Hearing loss attributed to desferrioxamine in patients with beta‐thalassaemia major

1987 ◽  
Vol 147 (4) ◽  
pp. 177-179 ◽  
Author(s):  
Peter S. Barrati ◽  
Ian R.G. Toogood
Keyword(s):  
Hearing Loss ◽  
Thalassaemia Major ◽  
Beta Thalassaemia

Marrow proliferation as a cause of hearing loss in beta-thalassaemia major

2007 ◽  
Vol 122 (11) ◽  
pp. 1253-1256 ◽  
Author(s):  
D Thio ◽  
V Prasad ◽  
P Anslow ◽  
P Lennox
Keyword(s):  
Hearing Loss ◽  
Chelation Therapy ◽  
Disease Process ◽  
Iron Chelation ◽  
Ossicular Chain ◽  
Thalassaemia Major ◽  
Beta Thalassaemia ◽  
Marrow Expansion ◽  
Desferrioxamine Therapy ◽  
New Onset

AbstractObjective:The aim of this report was to highlight the fact that hearing loss in thalassaemia patients can be related to marrow expansion affecting the ossicles, resulting in a conductive loss.Case report:A six-year-old boy with transfusion-dependent beta-thalassaemia developed a unilateral hearing loss shortly after commencing desferrioxamine therapy. Otoxicity was assumed, but the deficit was later found to be of a conductive nature, due to marrow proliferation within the ossicular chain as a consequence of the disease process – a phenomenon previously unreported in the literature.Conclusion:It is important to elucidate the precise nature of new onset hearing loss in patients receiving iron chelation therapy, in order to avoid unnecessary cessation of much needed medication, on the assumption of ototoxicity.

Reproductive health issues in female patients with beta-thalassaemia major: a narrative literature review

2020 ◽  
Vol 40 (7) ◽  
pp. 902-911 ◽  
Author(s):  
Malihe Nourollahpour Shiadeh ◽  
Elena Cassinerio ◽  
Maryam Modarres ◽  
Armin Zareiyan ◽  
Zeinab Hamzehgardeshi ◽  
...  
Keyword(s):  
Reproductive Health ◽  
Literature Review ◽  
Thalassaemia Major ◽  
Health Issues ◽  
Female Patients ◽  
Beta Thalassaemia ◽  
Narrative Literature ◽  
Narrative Literature Review

Porphyria cutanea tarda and beta-thalassaemia major: causal or casual?

2010 ◽  
Vol 24 (10) ◽  
pp. 1242-1243 ◽  
Author(s):  
P Papadantonakis ◽  
O Neofotistou ◽  
A Vasiliadi ◽  
A Skoutelis ◽  
A Tsatsakis ◽  
...  
Keyword(s):  
Porphyria Cutanea Tarda ◽  
Thalassaemia Major ◽  
Beta Thalassaemia

scholarly journals Effectiveness and Safety of Sitagliptin in Patients with Beta-thalassaemia Major and Diabetes Mellitus: A Case Series

2016 ◽  
Vol 9 (1) ◽  
pp. e2017004 ◽  
Author(s):  
Shahrzad Zonoozi
Keyword(s):  
Diabetes Mellitus ◽  
Case Series ◽  
Close Monitoring ◽  
Thalassaemia Major ◽  
Efficacy And Safety ◽  
Antidiabetic Agent ◽  
Retrospective Case ◽  
Beta Thalassaemia ◽  
Equivalent Reduction

Sitagliptin, a modern antidiabetic agent which is weight neutral and associated with low rate of hypoglycaemias, is being increasingly used in type 2 diabetes mellitus (DM). However there is paucity of data about its efficacy and safety in beta-thalassaemia major (β-TM).This retrospective case series of five patients (mean age of 45 years) is the first study evaluating the use of sitagliptin in patients with β-TM and DM.Four patients responded well to sitagliptin, as evidenced by decrease in fructosamine by 77 and 96µmol/L (equivalent reduction in HbA1c of 1.5% and 1.9%) observed in two patients and reduction in the frequency of hypoglycaemia without worsening glycaemic control in two others. One patient did not respond to sitagliptin. No patients reported significant side effects.This study provides evidence that sitagliptin may be considered, with caution, for use in patients with β-TM and DM, under the close monitoring of a Diabetologist.

Sign in / Sign up

Export Citation Format

Share Document